Literature DB >> 21862121

Effects of chitosan-nanoparticle-mediated tight junction opening on the oral absorption of endotoxins.

Kiran Sonaje1, Kun-Ju Lin, Michael T Tseng, Shiaw-Pyng Wey, Fang-Yi Su, Er-Yuan Chuang, Chia-Wei Hsu, Chiung-Tong Chen, Hsing-Wen Sung.   

Abstract

Recently, we reported a pH-responsive nanoparticle (NP) system shelled with chitosan (CS), which could effectively increase the oral absorption of insulin and produce a hypoglycemic effect, presumably due to the CS-mediated tight junction (TJ) opening. It has been often questioned whether CS can also enhance the absorption of endotoxins present in the small intestine. To address this concern, we studied the effect of CS NPs on the absorption of lipopolysaccharide (LPS), the most commonly found toxin in the gastrointestinal tract. To follow their biodistribution by the single-photon emission computed tomography/computed tomography, LPS and insulin were labeled with (99m)Tc-pertechnetate ((99m)Tc-LPS) and (123)iodine ((123)I-insulin), respectively. The (99m)Tc-LPS was ingested 1 h prior to the administration of the (123)I-insulin-loaded NPs to mimic the physiological conditions. The confocal and TEM micrographs show that the orally administered CS NPs were able to adhere and infiltrate through the mucus layer, approach the epithelial cells and mediate to open their TJs. The radioactivity associated with LPS was mainly restricted to the gastrointestinal tract, whereas (123)I-insulin started to appear in the urinary bladder at 3 h post administration. This observation indicates that the insulin-loaded in CS NPs can traverse across the intestinal epithelium and enter the systemic circulation, whereas LPS was unable to do so, probably because of the charge repulsion between the anionic LPS in the form of micelles and the negatively charged mucus layer. Our in vivo toxicity study further confirms that the enhancement of paracellular permeation by CS NPs did not promote the absorption of LPS. These results suggest that CS NPs can be used as a safe carrier for oral delivery of protein drugs.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21862121     DOI: 10.1016/j.biomaterials.2011.07.086

Source DB:  PubMed          Journal:  Biomaterials        ISSN: 0142-9612            Impact factor:   12.479


  17 in total

Review 1.  Safety concerns over the use of intestinal permeation enhancers: A mini-review.

Authors:  Fiona McCartney; John P Gleeson; David J Brayden
Journal:  Tissue Barriers       Date:  2016-04-12

Review 2.  Polymeric nanoparticle drug delivery technologies for oral delivery applications.

Authors:  Eric M Pridgen; Frank Alexis; Omid C Farokhzad
Journal:  Expert Opin Drug Deliv       Date:  2015-03-26       Impact factor: 6.648

Review 3.  In vitro and in vivo models for the study of oral delivery of nanoparticles.

Authors:  Jennifer M Gamboa; Kam W Leong
Journal:  Adv Drug Deliv Rev       Date:  2013-02-13       Impact factor: 15.470

4.  Overcoming Multiple Absorption Barrier for Insulin Oral Delivery Using Multifunctional Nanoparticles Based on Chitosan Derivatives and Hyaluronic Acid.

Authors:  Zuxian Chen; Shangcong Han; Xiaotang Yang; Lisa Xu; Hong Qi; Guizhou Hao; Jie Cao; Yan Liang; Qingming Ma; Guimin Zhang; Yong Sun
Journal:  Int J Nanomedicine       Date:  2020-07-09

Review 5.  Nanovesicles-Mediated Drug Delivery for Oral Bioavailability Enhancement.

Authors:  Yuehong Ren; Linghui Nie; Shiping Zhu; Xingwang Zhang
Journal:  Int J Nanomedicine       Date:  2022-10-17

6.  Acute macrovascular dysfunction in patients with type 2 diabetes induced by ingestion of advanced glycated β-lactoglobulins.

Authors:  Alin Stirban; Paraskevi Kotsi; Knut Franke; Ulf Strijowski; Weijing Cai; Christian Götting; Diethelm Tschoepe
Journal:  Diabetes Care       Date:  2012-12-13       Impact factor: 19.112

7.  Intranasal exposure to amorphous nanosilica particles could activate intrinsic coagulation cascade and platelets in mice.

Authors:  Tokuyuki Yoshida; Yasuo Yoshioka; Saeko Tochigi; Toshiro Hirai; Miyuki Uji; Ko-ichi Ichihashi; Kazuya Nagano; Yasuhiro Abe; Haruhiko Kamada; Shin-Ichi Tsunoda; Hiromi Nabeshi; Kazuma Higashisaka; Tomoaki Yoshikawa; Yasuo Tsutsumi
Journal:  Part Fibre Toxicol       Date:  2013-08-20       Impact factor: 9.400

8.  Biocompatibility of chitosan carriers with application in drug delivery.

Authors:  Susana Rodrigues; Marita Dionísio; Carmen Remuñán López; Ana Grenha
Journal:  J Funct Biomater       Date:  2012-09-17

9.  Polysaccharide-based micelles for drug delivery.

Authors:  Nan Zhang; Patricia R Wardwell; Rebecca A Bader
Journal:  Pharmaceutics       Date:  2013-05-27       Impact factor: 6.321

10.  The role of lipid-based nano delivery systems on oral bioavailability enhancement of fenofibrate, a BCS II drug: comparison with fast-release formulations.

Authors:  Tengfei Weng; Jianping Qi; Yi Lu; Kai Wang; Zhiqiang Tian; Kaili Hu; Zongning Yin; Wei Wu
Journal:  J Nanobiotechnology       Date:  2014-09-24       Impact factor: 10.435

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.